Oslo, 13 October 2024: Reference is made to the stock exchange announcement
published by Navamedic ASA (the "Company") on 7 October 2025, regarding the
final result of the rights issue in the Company, where a total of 6,046,511
shares were allocated at a subscription price of NOK 21.50 per share, (the
"Offer Shares") and the resolution to issue 272,090 new shares, at a
subscription price of NOK 21.50 per share, (the "Underwriting Commission
Shares") to the underwriters of the Rights issue as settlement of their
entitlement to underwriting commission.

The share capital increases pertaining to the issuance of the Offer Shares and
the Underwriting Commission Shares have today been registered with the Norwegian
Register of Business Enterprises (Nw. Foretaksregisteret).

The Company's registered share capital following the share capital increases is
NOK 17,746,219.72, divided into 23,981,378 shares, each with a nominal value of
NOK 0.74.

For more information, please contact:

Kathrine Elisabeth Gamborg Andreassen, CEO, Navamedic ASA

Tel: +47 951 78 880

Email: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic ASA

Tel: +47 917 62 842

Email: lars.hjarrand@navamedic.com

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

About Navamedic ASA

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in Greece.
Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.